Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic Impairment
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Celgene
Age
18–75
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Body mass index (BMI) between 18 and 40 kg/m\^2 (inclusive), and body weight ≥ 50 kg.
Participants have moderate HI (Group A), severe HI (Group B) or cirrhosis due to chronic hepatic disease and/or prior alcohol use.
Participants have moderate (Group A) or severe (Group B) HI as defined by National Cancer Institute-Organ Dysfunction Working Group (NCI-ODWG) criteria.
Participants must have liver-related laboratory test results within the respective reference ranges or with clinically insignificant excursions as agreed by the investigator and the Sponsor Medical Monitor.
Participants must be free of any clinically significant disease that would interfere with the study evaluations.
You may not be if
Any surgical or medical condition possibly affecting drug absorption, distribution, metabolism, and excretion (ADME).
History of major surgery within 8 weeks before the study intervention administration.
Any other clinically significant medical, psychiatric, and/or social reason, or other active issues, as determined by the investigator.
Clareo Health | Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic Impairment
